Pasithea Therapeutics Corp. (KTTA) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Pasithea Therapeutics Corp. (KTTA) Earnings Overview
As of June 28, 2026, Pasithea Therapeutics Corp. (KTTA) reported trailing twelve-month net income of -$20M, reflecting +77.1% year-over-year growth. The company earned $-2.81 per diluted share over the past four quarters.
Looking at the long-term picture, KTTA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$61,476 in fiscal 2020.
Pasithea Therapeutics Corp. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CMPS (-$179M net income), ATAI (-$663M net income, -16142.0% margin), MNMD (-$238M net income), KTTA has comparable earnings metrics. Compare KTTA vs CMPS →
KTTA Earnings vs Peers
Earnings metrics vs comparable public companies
KTTA Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$20M | -46.9% | -$21M | $-2.91 | - | - |
| 2024 | -$14M | +12.9% | -$14M | $-12.69 | - | - |
| 2023 | -$16M | -14.5% | -$16M | $-13.01 | - | - |
| 2022 | -$14M | -541.2% | -$13M | $-10.34 | - | - |
| 2021 | -$2M | -3435.6% | -$5M | $-1.89 | -14430.5% | -29925.7% |
| 2020 | $-61,476 | - | $-61,476 | $-0.06 | - | - |
Download Data
Export KTTA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KTTA — Frequently Asked Questions
Quick answers to the most common questions about buying KTTA stock.
What is KTTA earnings per share (EPS)?
KTTA trailing twelve-month (TTM) diluted EPS is $-2.81, reflecting +77.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Pasithea Therapeutics Corp.'s net income?
Pasithea Therapeutics Corp. (KTTA) trailing twelve-month net income is $-20M as of 2025. Earnings grew +77.1% year-over-year.
Is KTTA profitable?
KTTA is not currently profitable on a TTM basis, reporting a net loss of $-20M. Net margin is N/A. Investors should monitor for a return to profitability.
What is KTTA's earnings growth rate?
KTTA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are KTTA's profit margins?
Pasithea Therapeutics Corp. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -58.4%.
Is KTTA growing earnings?
Yes, KTTA earnings are accelerating — EPS growth of +77.1% exceeds the 5-year CAGR of N/A. TTM net income reached $-20M. Earnings momentum is strengthening.
What was KTTA's best earnings year?
Pasithea Therapeutics Corp.'s highest annual net income on record is $-61476.00, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were KTTA's earnings last quarter?
KTTA's most recent reported quarter was Q1 2026. Net income was $-3M with diluted EPS of $-0.41. For a full breakdown of all quarters, see the quarterly earnings table on this page.